000 03480nam a22005175i 4500
001 978-1-60761-266-7
003 DE-He213
005 20140220083734.0
007 cr nn 008mamaa
008 101029s2011 xxu| s |||| 0|eng d
020 _a9781607612667
_9978-1-60761-266-7
024 7 _a10.1007/978-1-60761-266-7
_2doi
050 4 _aRB45
072 7 _aMJF
_2bicssc
072 7 _aMED038000
_2bisacsh
082 0 4 _a616.15
_223
100 1 _aVerstovsek, Srdan.
_eeditor.
245 1 0 _aMyeloproliferative Neoplasms
_h[electronic resource] :
_bBiology and Therapy /
_cedited by Srdan Verstovsek, Ayalew Tefferi.
264 1 _aTotowa, NJ :
_bHumana Press :
_bImprint: Humana Press,
_c2011.
300 _aX, 230 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aContemporary Hematology
505 0 _aChapter 1 - Diagnosis and Classification of the BCR-ABL-negative Myeloproliferative Neoplasms -- Chapter 2 - Genetics of the Myeloproliferative Neoplasms -- Chapter 3 - Cytogenetic Findings in Classic Myeloproliferative Neoplasms -- Chapter 4 - Prognostic Factors in Classic Myeloproliferative Neoplasms -- Chapter 5 - Therapy of Polycythemia Vera and Essential Thrombocythemia -- Chapter 6 - Conventional and Investigational Therapy for Primary Myelofibrosis -- Chapter 7 - Hematopoietic Cell Transplantation for Myelofibrosis -- Chapter 8 - JAK2 Inhibitors as Therapy for Classic Myeloproliferative Neoplasms -- Chapter 9 - Blastic Transformation of Classic Myeloproliferative Neoplasms -- Chapter 10 - Eosinophilic Disorders: Differential Diagnosis and Management -- Chapter 11 - Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosi.
520 _aThis succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.
650 0 _aMedicine.
650 0 _aAngiography.
650 0 _aHematology.
650 0 _aBiochemistry.
650 0 _aOncology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aHematology.
650 2 4 _aOncology.
650 2 4 _aAngiology.
650 2 4 _aMedical Biochemistry.
700 1 _aTefferi, Ayalew.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781607612650
830 0 _aContemporary Hematology
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-60761-266-7
912 _aZDB-2-SME
999 _c106357
_d106357